Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CADL

CADL - Candel Therapeutics, Inc. Stock Price, Fair Value and News

$5.74-0.36 (-5.90%)
Market Closed

22/100

CADL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

22/100

CADL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.96

Target 3M

$5.58

Target 6M

$5.27

CADL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CADL Price Action

Last 7 days

-8.9%

Last 30 days

-1.0%

Last 90 days

2.9%

Trailing 12 Months

-14.3%

CADL RSI Chart

CADL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CADL Valuation

Market Cap

315.1M

Price/Earnings (Trailing)

-13.85

Price/Sales (Trailing)

101.55

Price/Free Cashflow

-9.34

CADL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.96

Target 3M

$5.58

Target 6M

$5.27

CADL Fundamentals

CADL Revenue

Revenue (TTM)

3.1M

Rev. Growth (Yr)

303.81%

Rev. Growth (Qtr)

2.92%

CADL Earnings

Earnings (TTM)

-22.8M

Earnings Growth (Yr)

-5.85%

Earnings Growth (Qtr)

-134.97%

CADL Profitability

Return on Equity

-28.4%

Return on Assets

-24.32%

Free Cashflow Yield

-10.71%

CADL Investor Care

Shares Dilution (1Y)

69.05%

Diluted EPS (TTM)

-0.56

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.7M2.4M3.1M0
20241.3M1.5M1.2M1.1M
202300595.5K979.5K
2022124.5K124.5K125.0K124.5K
2021124.9K124.8K124.6K124.5K
2020000125.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Candel Therapeutics, Inc.

CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
 CEO
 WEBSITEcandeltx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES76

Candel Therapeutics, Inc. Frequently Asked Questions

CADL is the stock ticker symbol of Candel Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Candel Therapeutics, Inc. is 315.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check CADL's fair value in chart for subscribers.

The fair value guage provides a quick view whether CADL is over valued or under valued. Whether Candel Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Candel Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CADL.

As of Wed Jan 28 2026, CADL's PE ratio (Price to Earnings) is -13.85 and Price to Sales (PS) ratio is 101.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CADL PE ratio will change depending on the future growth rate expectations of investors.